Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: CrazyPete who wrote (23738)	5/22/2007 12:38:26 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Cougar3's pooled analysis is not a valid method for combining data across experiments with different sample ascertainment. You are right of course - the issue is that here the ADOPT trial both had a higher cardiac event rate than the other trials and is 2:1 weighted in favor of the placebo group, and so it swamps the other trials when you pool them. But why total up the number of infarcts with and without the drug across the trials then? And what is the basis for excluding trials where there were no events? If they had not done that then I bet the overall p value would have dropped below significance. Peter